Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/STYX_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/STYX_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/STYX_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/STYX_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719327 | Esophagus | HGIN | intrinsic apoptotic signaling pathway | 90/2587 | 288/18723 | 1.50e-14 | 2.80e-12 | 90 |
GO:200124227 | Esophagus | HGIN | regulation of intrinsic apoptotic signaling pathway | 58/2587 | 164/18723 | 2.57e-12 | 3.58e-10 | 58 |
GO:200123327 | Esophagus | HGIN | regulation of apoptotic signaling pathway | 97/2587 | 356/18723 | 1.36e-11 | 1.57e-09 | 97 |
GO:200124410 | Esophagus | HGIN | positive regulation of intrinsic apoptotic signaling pathway | 25/2587 | 58/18723 | 4.91e-08 | 2.75e-06 | 25 |
GO:200123519 | Esophagus | HGIN | positive regulation of apoptotic signaling pathway | 41/2587 | 126/18723 | 6.06e-08 | 3.22e-06 | 41 |
GO:001063920 | Esophagus | HGIN | negative regulation of organelle organization | 79/2587 | 348/18723 | 4.12e-06 | 1.37e-04 | 79 |
GO:19021156 | Esophagus | HGIN | regulation of organelle assembly | 46/2587 | 186/18723 | 4.63e-05 | 1.12e-03 | 46 |
GO:004593626 | Esophagus | HGIN | negative regulation of phosphate metabolic process | 89/2587 | 441/18723 | 1.24e-04 | 2.54e-03 | 89 |
GO:001056326 | Esophagus | HGIN | negative regulation of phosphorus metabolic process | 89/2587 | 442/18723 | 1.34e-04 | 2.71e-03 | 89 |
GO:000647017 | Esophagus | HGIN | protein dephosphorylation | 61/2587 | 281/18723 | 1.86e-04 | 3.51e-03 | 61 |
GO:003530425 | Esophagus | HGIN | regulation of protein dephosphorylation | 24/2587 | 90/18723 | 9.27e-04 | 1.17e-02 | 24 |
GO:00340638 | Esophagus | HGIN | stress granule assembly | 10/2587 | 26/18723 | 1.60e-03 | 1.79e-02 | 10 |
GO:19021162 | Esophagus | HGIN | negative regulation of organelle assembly | 13/2587 | 41/18723 | 2.62e-03 | 2.58e-02 | 13 |
GO:005134620 | Esophagus | HGIN | negative regulation of hydrolase activity | 72/2587 | 379/18723 | 2.81e-03 | 2.75e-02 | 72 |
GO:004366619 | Esophagus | HGIN | regulation of phosphoprotein phosphatase activity | 16/2587 | 58/18723 | 4.35e-03 | 3.84e-02 | 16 |
GO:003530320 | Esophagus | HGIN | regulation of dephosphorylation | 29/2587 | 128/18723 | 4.41e-03 | 3.87e-02 | 29 |
GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
GO:0006913110 | Esophagus | ESCC | nucleocytoplasmic transport | 230/8552 | 301/18723 | 6.04e-28 | 2.02e-25 | 230 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STYX | SNV | Missense_Mutation | | c.599G>A | p.Gly200Asp | p.G200D | Q8WUJ0 | protein_coding | deleterious(0.03) | possibly_damaging(0.832) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STYX | SNV | Missense_Mutation | | c.87N>A | p.Met29Ile | p.M29I | Q8WUJ0 | protein_coding | tolerated(0.16) | benign(0.149) | TCGA-C8-A12P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STYX | SNV | Missense_Mutation | novel | c.451N>G | p.Gln151Glu | p.Q151E | Q8WUJ0 | protein_coding | deleterious(0.04) | possibly_damaging(0.729) | TCGA-VS-A9UP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
STYX | SNV | Missense_Mutation | novel | c.349C>A | p.Leu117Ile | p.L117I | Q8WUJ0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
STYX | insertion | Frame_Shift_Ins | rs769509399 | c.290_291insT | p.Met101TyrfsTer3 | p.M101Yfs*3 | Q8WUJ0 | protein_coding | | | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STYX | SNV | Missense_Mutation | novel | c.428N>G | p.Tyr143Cys | p.Y143C | Q8WUJ0 | protein_coding | tolerated(0.06) | benign(0.333) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STYX | SNV | Missense_Mutation | | c.80N>A | p.Arg27Gln | p.R27Q | Q8WUJ0 | protein_coding | deleterious(0) | possibly_damaging(0.499) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
STYX | SNV | Missense_Mutation | | c.289N>T | p.Arg97Cys | p.R97C | Q8WUJ0 | protein_coding | tolerated(0.06) | benign(0.031) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STYX | SNV | Missense_Mutation | novel | c.377N>T | p.Arg126Ile | p.R126I | Q8WUJ0 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
STYX | SNV | Missense_Mutation | | c.665N>C | p.Asn222Thr | p.N222T | Q8WUJ0 | protein_coding | tolerated_low_confidence(0.08) | benign(0.19) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |